2-((2-chloro-5-methylpyrimidin-4-yl)amino)-N-methylbenzamide | 1022964-14-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-((2-chloro-5-methylpyrimidin-4-yl)amino)-N-methylbenzamide
• 英文别名: 2-(2-Chloro-5-methyl-pyrimidin-4-ylamino)-N-methyl-benzamide；2-[(2-chloro-5-methylpyrimidin-4-yl)amino]-N-methylbenzamide
• CAS: 1022964-14-2
• 化学式: C₁₃H₁₃ClN₄O
• 分子量: 276.725
• InChiKey: SNLZBDPWAUJBFK-UHFFFAOYSA-N

物化性质

• 沸点：
  527.2±40.0 °C(Predicted)
• 密度：
  1.314±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  66.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-((2-chloro-5-methylpyrimidin-4-yl)amino)-N-methylbenzamide 在 potassium phosphate 、 palladium diacetate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities

  摘要：

  A series of 2,4-diarylaminopyrimidine derivatives containing dithiocarbamate moiety were designed by molecular hybridization strategy and synthesized for screening as inhibitors of focal adhesion kinase (FAK). Most of these compounds exhibit significant antiproliferative activities on human cancer cell lines expressing high levels of FAK at nanomolar concentrations. The compound 14z was identified as the most potent FAK inhibitor among these candidates. 14z has excellent anti-proliferative effect with IC50 values from 0.001 mu M to 0.06 mu M on HCT116, PC-3, U87-MG and MCF-7 cell lines and relatively less cytotoxicity to a nonmalignant cell line MCF-10A compared with MCF-7 cells (S1 value > 10). 14z also exhibits significant FAK inhibitory activity (IC50=0.07 nM). In addition, compound 14z causes cell cycle arrest at G2/M and prompted apoptosis in both HCT116 and MCF-7 cells in a dose-dependent manner. Further studies show that compound 14z inhibits migration of MCF-7 and has anti-angiogenesis effect on HUVEC cells. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.05.048
• 作为产物：
  描述：

  N-甲基-2-硝基苯甲酰胺 在 水 、 铁粉 、 sodium hydride 、 氯化铵 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 26.0h， 生成 2-((2-chloro-5-methylpyrimidin-4-yl)amino)-N-methylbenzamide
  参考文献：
  名称：

  作为FAK抑制剂的氨基二硫代甲酸酯类化合 物

  摘要：

  本发明的目的是提供一种作为FAK抑制剂的氨基二硫代甲酸酯类化合物及其药物组合物、制备方法和用途。该化合物具有如下通式(Ⅰ)所示的结构。

  公开号：

  CN111072571B

文献信息

• ANTHRANILAMIDE INHIBITORS OF AURORA KINASE
  申请人：Johnson Neil W.

  公开号：US20080182852A1

  公开（公告）日：2008-07-31

  The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof; where R 1 , R 2 , R 3 , R 4 , r and s are as previously defined. Compounds of the present invention are useful in the treatment of diseases associated with Aurora kinase activity such as cancer.

  本发明涉及以下公式所代表的化合物： 或其药学上可接受的盐； 其中R1、R2、R3、R4、r和s如前所定义。本发明的化合物在治疗与Aurora激酶活性相关的疾病，如癌症方面是有用的。
• 作为FAK抑制剂的氨基二硫代甲酸酯类化合 物
  申请人：北京西博医药研究有限公司

  公开号：CN111072571B

  公开（公告）日：2021-05-14

  本发明的目的是提供一种作为FAK抑制剂的氨基二硫代甲酸酯类化合物及其药物组合物、制备方法和用途。该化合物具有如下通式(Ⅰ)所示的结构。
• FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS
  申请人：Ahmed Gulzar

  公开号：US20090221555A1

  公开（公告）日：2009-09-03

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , and A 5 , are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供公式I或II化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5如本文所定义。公式I或II化合物具有ALK和/或c-Met抑制活性，可用于治疗增殖性疾病。
• Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors
  申请人：Ahmed Gulzar

  公开号：US20120165519A1

  公开（公告）日：2012-06-28

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , and A 5 , are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了式I或II的化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5如本文所定义。式I或II的化合物具有ALK和/或c-Met抑制活性，并可用于治疗增生性疾病。
• Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors
  申请人：Ahmed Gulzar

  公开号：US08552186B2

  公开（公告）日：2013-10-08

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了式I或II的化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5的定义如本文所述。式I或II的化合物具有ALK和/或c-Met抑制活性，可用于治疗增殖性疾病。